Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4
Ran Bi1, Yuyou Deng1, Chao Tang1
1Department of Urology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Abstract:
Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, with minimal toxicity to normal tissues. However, accumulating evidence suggests that certain cancer types are insensitive to TRAIL signaling. The aim of this study was to identify an effective combination regimen, which can overcome TRAIL resistance in renal cancer cell. Herein, we found that human renal carcinoma cells (RCCs) are widely resistant to TRAIL‑mediated growth inhibition and subsequently identified that andrographolide (Andro), a major constituent of Andrographis paniculate, an annual herbaceous plant in the family Acanthaceae, counteracts TRAIL resistance in RCCs. Combined treatment with TRAIL and Andro suppressed cell viability as determined by MTS and proliferation as determined by EdU in a dose‑dependent manner and inactivated the clonogenic and migration ability of RCCs. Andro significantly enhances TRAIL‑mediated cell cycle arrest at the G2/M phase as determined by flow cytometry and senescence. Moreover, Andro restored TRAIL signaling, which in turns activated pro‑apoptosis caspases as determined by immunoblot assay. The TRAIL receptor, death receptor (DR)4, but not DR5, was found to be significantly upregulated in Andro‑treated RCC cells, which contributed to the role of Andro as a TRAIL sensitizer. The present study demonstrated that the combined treatment of Andro and TRAIL has potential therapeutic value against renal cancer.
Insights
Andrographolide (Andro) sensitizes resistant renal cancer cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) therapy. This combination effectively inhibits cancer cell viability, proliferation, and migration, offering potential for renal cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells.
- Certain cancer types, including renal carcinoma cells (RCCs), exhibit resistance to TRAIL-mediated apoptosis.
- Developing strategies to overcome TRAIL resistance is crucial for effective cancer therapy.
Purpose of the Study:
- To identify an effective combination regimen to overcome TRAIL resistance in renal cancer cells.
- To investigate the potential of andrographolide (Andro) as a TRAIL sensitizer in RCCs.
Main Methods:
- Human renal carcinoma cells (RCCs) were treated with TRAIL and andrographolide (Andro).
- Cell viability was assessed using MTS assays, proliferation by EdU incorporation, and clonogenic/migration abilities were evaluated.
- Cell cycle arrest and senescence were analyzed by flow cytometry.
- Apoptosis-related protein expression and TRAIL receptor (DR4, DR5) levels were determined by immunoblot assay.
Main Results:
- Andro counteracted TRAIL resistance in RCCs, suppressing cell viability, proliferation, and migration in a dose-dependent manner.
- Combined TRAIL and Andro treatment induced significant G2/M phase cell cycle arrest and senescence.
- Andro restored TRAIL signaling, activating pro-apoptotic caspases and upregulating the TRAIL receptor DR4.
- DR4 upregulation by Andro contributed to its role as a TRAIL sensitizer.
Conclusions:
- Combined treatment with andrographolide and TRAIL demonstrates significant therapeutic potential against renal cancer.
- Andrographolide effectively sensitizes TRAIL-resistant renal cancer cells by upregulating DR4 and restoring TRAIL-induced apoptosis.
- This combination therapy offers a promising strategy for overcoming TRAIL resistance in renal cancer treatment.


